VEROSUDIL HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H17N3O2S.ClH
Molecular Weight	363.862
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CN(C)C(C(=O)NC1=CC2=C(C=C1)C(=O)NC=C2)C3=CSC=C3

InChI

InChIKey=FUBBJNODZIIYHW-UHFFFAOYSA-N

InChI=1S/C17H17N3O2S.ClH/c1-20(2)15(12-6-8-23-10-12)17(22)19-13-3-4-14-11(9-13)5-7-18-16(14)21;/h3-10,15H,1-2H3,(H,18,21)(H,19,22);1H

HIDE SMILES / InChI

Molecular Formula	C17H17N3O2S
Molecular Weight	327.401
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://adisinsight.springer.com/drugs/800031137 | https://www.pharmacodia.com/yaodu/html/v1/chemicals/42b5ce9d23645f2bae146063b2218ae7.html

Verosudil (AR-12286) is a selective Rho-kinase inhibitor for the treatment of glaucoma and ocular hypertension being developed by Aerie Pharmaceuticals in the US. Verosudil was in phase II/III clinical trials for the treatment of glaucoma and in phase II clinical trials for the treatment of ocular hypertension.

Originator

Approval Year

PubMed

Title	Date	PubMed
Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension.	2011 Nov	21794845
Efficacy of Topically Administered Rho-Kinase Inhibitor AR-12286 in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma.	2016 Sep	27552517

Patents

Sample Use Guides

In Vivo Use Guide

0.05%, 0.1% and 0.25% Verosudil (AR-12286) ophthalmic solutions in patients diagnosed with ocular hypertension or glaucoma. All 3 concentrations of AR-12286 produced statistically and clinically significant reductions in mean IOP that were dose dependent, with peak effects occurring 2 to 4 hours after dosing. Mean IOP at peak effect ranged from 17.6 to 18.7 mm Hg (-6.8 to -4.4 mm Hg) for the 3 concentrations. The largest IOP reductions were produced by 0.25% AR-12286 after twice daily dosing (up to -6.8 mm Hg; 28%). The 0.25% concentration dosed once-daily in the evening produced highly significant IOP reductions throughout the following day (-5.4 to -4.2 mm Hg).

Route of Administration: Topical

Substance Class	Chemical Created by `admin` on `Fri Dec 15 19:17:48 GMT 2023` Edited by `admin` on `Fri Dec 15 19:17:48 GMT 2023`
Record UNII	S47W900F0N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VEROSUDIL HYDROCHLORIDE

Official Name

English

3-THIOPHENEACETAMIDE, N-(1,2-DIHYDRO-1-OXO-6-ISOQUINOLINYL)-.ALPHA.-(DIMETHYLAMINO)-, HYDROCHLORIDE (1:1)

Systematic Name

English

VEROSUDIL HYDROCHLORIDE [USAN]

Common Name

English

AR-12286

Code

English

Verosudil hydrochloride [WHO-DD]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29705